Wearing the scars of commercialisation Skin cell based therapies Tissue engineering solutions have been applied to skin many decades. The focus was on the development of epithelial cell-based solutions alongside the development of dermal scaffolds for the use in large surface area bun injuries when the available donor sites were limited. The capacity to grow cells in culture led to laboratory-based tissue expansion with large areas of wound cover possible form a small donor site. The drawback was the time taken to culture the cells, the cost to do so, and the complexity of use. The development of a point of care medical device to harvest an autologous epithelial cell suspension ReCell was developed to reduce the time between cell harvest and treatment with reduction in cost. The reduction in time to healing was associated with reduction in scarring and in the length of stay. With the IP assigned to a not for profit foundation the team established a company to commercialise the device focused on making the technology available and supporting the ongoing research. To realise the potential of the developing technologies needs alignment of not only the science and engineering but also the commercial upscaling of production in a safe and regulated framework for clinical use. In addition the education and training for the introduction of new technology within the health system is essential, bringing together the technology and systems for utilisation to optimise the patient outcome. The journey from bench to bedside will be presented